Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 930270
                    [Title] => FDA reviewing heart risks of Glaxo diabetes pill
                    [Summary] => 
The Food and Drug Administration will hold a meeting in June to reassess the safety of GlaxoSmithKline's former blockbuster drug Avandia, which was severely restricted in 2010 due to concerns about its impact on the heart.

                    [DatePublished] => 2013-04-13 08:00:08
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => World
                    [SectionUrl] => world
                    [URL] => 
                )

        )

)

Mary Anne Rhyne

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 930270
                    [Title] => FDA reviewing heart risks of Glaxo diabetes pill
                    [Summary] => 
The Food and Drug Administration will hold a meeting in June to reassess the safety of GlaxoSmithKline's former blockbuster drug Avandia, which was severely restricted in 2010 due to concerns about its impact on the heart.

                    [DatePublished] => 2013-04-13 08:00:08
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => World
                    [SectionUrl] => world
                    [URL] => 
                )

        )

)

abtest

FDA reviewing heart risks of Glaxo diabetes pill

April 13, 2013 - 8:00am

The Food and Drug Administration will hold a meeting in June to reassess the safety of GlaxoSmithKline's former blockbuster drug Avandia, which was severely restricted in 2010 due to concerns about its impact on...

World